Pulmonary Arterial Hypertension (PAH) is an orphan disease, incurable that remains highly lethal despite recent advanced medical treatment.
Various pharmacological therapies such as Prostacyclines, Endothelin receptor antagonists, PDE5 inhibitors have been reported for PAH diseases. In spite of these treatments, the average of survival is 2,8 years so new treatments must be developed.
This growing recognition of these health problems, and their risks, increases our need for effective research, drug development and treatments. An essential component of developing new medicines in this therapeutic area is understanding the fundamental mechanisms of disease thanks to reliable in vivo models.
Since 2005, Syncrosome propose you to evaluate the efficacy of your compound in 2 validated models in rats with improved reference compounds:
- Monocrotaline induced PAH in rat: Development of a severe PAH by a chemical induction
- Chronic Hypoxia induced PAH in rat: Development of a moderate PAH by chronic hypoxia
So don’t hesitate to contact us and discuss about your projects!